Your browser doesn't support javascript.
loading
Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma.
Yamauchi, Masami; Ono, Atsushi; Amioka, Kei; Fujii, Yasutoshi; Nakahara, Hikaru; Teraoka, Yuji; Uchikawa, Shinsuke; Fujino, Hatsue; Nakahara, Takashi; Murakami, Eisuke; Okamoto, Wataru; Miki, Daiki; Kawaoka, Tomokazu; Tsuge, Masataka; Imamura, Michio; Hayes, C Nelson; Ohishi, Waka; Kishi, Takeshi; Kimura, Mizuki; Suzuki, Natsumi; Arihiro, Koji; Aikata, Hiroshi; Chayama, Kazuaki; Oka, Shiro.
  • Yamauchi M; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. myamauchi@hiroshima-u.ac.jp.
  • Ono A; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Amioka K; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Fujii Y; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Nakahara H; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Teraoka Y; Department of Clinical and Molecular Genetics, Hiroshima University, Hiroshima, Japan.
  • Uchikawa S; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Fujino H; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Nakahara T; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Murakami E; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Okamoto W; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Miki D; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Kawaoka T; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Tsuge M; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Imamura M; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Hayes CN; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Ohishi W; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Kishi T; Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima, Japan.
  • Kimura M; Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima, Japan.
  • Suzuki N; Oncology Department, HQs, Eisai Co., Ltd, Tokyo, Japan.
  • Arihiro K; Oncology Department, HQs, Eisai Co., Ltd, Tokyo, Japan.
  • Aikata H; Department of Anatomical Pathology, Hiroshima University Hospital, Hiroshima, Japan.
  • Chayama K; Department of Gastroenterology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
  • Oka S; Collaborative Research Laboratory of Medical Innovation, Hiroshima University, Hiroshima, Japan. chayama@mba.ocn.ne.jp.
Commun Med (Lond) ; 3(1): 152, 2023 Oct 25.
Article en En | MEDLINE | ID: mdl-37880538
Two types of therapy for liver cancer are immunotherapy and anti-angiogenic therapy. Immunotherapy helps the patient's immune system to attack the tumor. Anti-angiogenic therapy blocks the formation of new blood vessels (angiogenesis) in the tumor, and this type of therapy might also impact the immune system. We analyzed changes in the immune characteristics of human liver cancer samples induced by lenvatinib, an anti-angiogenic therapy. Patient outcomes on lenvatinib did not depend on the immune features of the tumor before treatment. However, immune characteristics of the tumors did change after treatment, and this may mean these tumors become easier to treat with immunotherapies. These findings help us to understand the effects of lenvatinib in liver cancer and whether, for example, it might be useful to combine this drug with immunotherapy.
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2023 Tipo del documento: Article